Telratolimod
Based on 10 publication(s) in Google Scholar
Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.44%
- CAS No.: 1359993-59-1
- Formule: C36H59N5O2
- Masse moléculaire:593.89
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Telratolimod
More- ACS Nano. 2022 Aug 23;16(8):13168-13182. [Abstract]
- Adv Sci (Weinh). 2025 Jun 11:e04886. [Abstract]
- Adv Sci (Weinh). 2023 Feb;10(5):e2206001. [Abstract]
- J Nanobiotechnology. 2024 May 29;22(1):296. [Abstract]
- J Immunother Cancer. 2025 Dec 12;13(12):e011665. [Abstract]
- ACS Cent Sci. 2022 Oct 26;8(10):1435-1446. [Abstract]
- JCI Insight. 2022 May 17;e146608. [Abstract]
- Front Public Health. 2023 Jan 6:10:976686. [Abstract]
- Biochem Biophys Res Commun. 2023 Apr 23:653:106-114. [Abstract]
- Patent. US20200316211A1.
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
IF
-
ELISA
-
Bio/Physico-chemical Assay
Activité biologique
|
TLR7 |
TLR8 |
Telratolimod (3M-052) is a toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1359993-59-1
-
Appearance Solid
-
Masse moléculaire 593.89
-
Formule C36H59N5O2
-
Color White to light yellow
-
SMILES
NC1=NC2=CC=CC=C2C3=C1N=C(CCCC)N3OCCCCNC(CCCCCCCCCCCCCCCCC)=O
-
Synonyms
MEDI9197; 3M-052
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
ACS Nano
Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy. [Abstract]2022 Aug 23;16(8):13168-13182. PMID: 35920660 -
Adv Sci (Weinh)
KRAS mRNA Spleen-Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer. [Abstract]2025 Jun 11:e04886. PMID: 40498983 -
Adv Sci (Weinh)
Adipocytes Encapsulating Telratolimod Recruit and Polarize Tumor-Associated Macrophages for Cancer Immunotherapy. [Abstract]2023 Feb;10(5):e2206001. PMID: 36526596
Telratolimod purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Feb;10(5):e2206001. [Abstract]
Telratolimod (0.2 mg/kg; intratumorally injection; single daily for 3 days) or Telratolimod loaded into the lipid droplets of adipocytes significantly inhibit growth of both original and distant tumor in vivo.
-
J Nanobiotechnology
A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune. [Abstract]2024 May 29;22(1):296. PMID: 38811964
Telratolimod purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 May 29;22(1):296. [Abstract]
UV-vis spectra of 3M-052 (Telratolimod), CM, UiO-66, NHWD-870, MCM@UN.
Telratolimod purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 May 29;22(1):296. [Abstract]
Insertion of the immunostimulant (3M-052 (Telratolimod)) into the lipid bilayer of cancer cell membranes through the lipid tail of 18 C. (Dil labeled cell membrane, FITC labeled 3M-052).
-
J Immunother Cancer
In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8+ T cell responses. [Abstract]2025 Dec 12;13(12):e011665. PMID: 41386973 -
ACS Cent Sci
Tumor Cell-Surface Binding of Immune Stimulating Polymeric Glyco-Adjuvant via Cysteine-Reactive Pyridyl Disulfide Promotes Antitumor Immunity. [Abstract]2022 Oct 26;8(10):1435-1446. PMID: 36313164
Telratolimod purchased from MedChemExpress. Usage Cited in: ACS Cent Sci. 2022 Oct 26;8(10):1435-1446. [Abstract]
MC38 tumor-bearing mice were injected intratumorally with p(Man-TLR7-PDS), control TLR7/8 agonist 3M-052 (Telratolimod), or PBS. Six hours after injection, sera were collected and analyzed for proinflammatory cytokines, including IFNγ, IL-6, MCP-1, IFNβ and IL-27.
-
JCI Insight
Coimmunomodulation of tumor and tumor-draining lymph nodes during in situ vaccination promotes antitumor immunity. [Abstract]2022 May 17;e146608. PMID: 35579961
Telratolimod purchased from MedChemExpress. Usage Cited in: JCI Insight. 2022 May 17;e146608. [Abstract]
Representative images of solutions containing micellar MEDI9197 before and after filtration. The numbers indicate molar ratio of MEDI9197 to DSPE-PEG-2000.
Telratolimod purchased from MedChemExpress. Usage Cited in: JCI Insight. 2022 May 17;e146608. [Abstract]
Loading efficacy of MEDI9197 (Telratolimod, 30-300 μg) at various molar ratios of MEDI9197 to DSPE-PEG-2000 (n = 4).
-
Front Public Health
SARS-CoV-2 delta (B.1.617.2) spike protein adjuvanted with Alum-3M-052 enhances antibody production and neutralization ability. [Abstract]2023 Jan 6:10:976686. PMID: 36684881 -
Biochem Biophys Res Commun
Anti-TNFR2 enhanced the antitumor activity of a new HMGN1/3M-052 stimulated dendritic cell vaccine in a mouse model of colon cancer. [Abstract]2023 Apr 23:653:106-114. PMID: 36868074 -
Solvant et solubilité
DMSO : 62.5 mg/mL (105.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 50 mg/mL (84.19 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (3.50 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (3.50 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (268 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 1.6838 mL | 8.4191 mL | 16.8381 mL | 42.0953 mL |
| 5 mM | 0.3368 mL | 1.6838 mL | 3.3676 mL | 8.4191 mL | |
| 10 mM | 0.1684 mL | 0.8419 mL | 1.6838 mL | 4.2095 mL | |
| 15 mM | 0.1123 mL | 0.5613 mL | 1.1225 mL | 2.8064 mL | |
| 20 mM | 0.0842 mL | 0.4210 mL | 0.8419 mL | 2.1048 mL | |
| 25 mM | 0.0674 mL | 0.3368 mL | 0.6735 mL | 1.6838 mL | |
| 30 mM | 0.0561 mL | 0.2806 mL | 0.5613 mL | 1.4032 mL | |
| 40 mM | 0.0421 mL | 0.2105 mL | 0.4210 mL | 1.0524 mL | |
| 50 mM | 0.0337 mL | 0.1684 mL | 0.3368 mL | 0.8419 mL | |
| 60 mM | 0.0281 mL | 0.1403 mL | 0.2806 mL | 0.7016 mL | |
| 80 mM | 0.0210 mL | 0.1052 mL | 0.2105 mL | 0.5262 mL | |
| DMSO | 100 mM | 0.0168 mL | 0.0842 mL | 0.1684 mL | 0.4210 mL |
Powered by Bioz